This site is intended for healthcare professionals

AzurRX acquires First Wave Bio and with it niclosamide.

Read time: 1 mins
Last updated:15th Sep 2021
Published:15th Sep 2021
AzurRx is assuming a new name through its acquisition of First Wave Bio. The cash-and-stock deal could be worth up to $229 million and includes future payments if development, regulatory and sales goals are met.
Type: industry
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest